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AbstrAct
Introduction Xeroderma pigmentosum (XP) is a rare 
genetic condition caused by defective nucleotide excision 
repair and characterised by skin cancer, ocular and 
neurological involvement. Stringent ultraviolet protection 
is the only way to prevent skin cancer. Despite the risks, 
some patients’ photoprotection is poor, with a potentially 
devastating impact on their prognosis. The aim of this 
research is to identify disease-specific and psychosocial 
predictors of photoprotection behaviour and ultraviolet 
radiation (UVR) dose to the face.
Methods and analysis Mixed methods research based 
on 45 UK patients will involve qualitative interviews to 
identify individuals’ experience of XP and the influences 
on their photoprotection behaviours and a cross-sectional 
quantitative survey to assess biopsychosocial correlates 
of these behaviours at baseline. This will be followed 
by objective measurement of UVR exposure for 21 
days by wrist-worn dosimeter and daily recording of 
photoprotection behaviours and psychological variables 
for up to 50 days in the summer months. This novel 
methodology will enable UVR dose reaching the face 
to be calculated and analysed as a clinically relevant 
endpoint. A range of qualitative and quantitative analytical 
approaches will be used, reflecting the mixed methods 
(eg, cross-sectional qualitative interviews, n-of-1 studies). 
Framework analysis will be used to analyse the qualitative 
interviews; mixed-effects longitudinal models will be used 
to examine the association of clinical and psychosocial 
factors with the average daily UVR dose; dynamic 
logistic regression models will be used to investigate 
participant-specific psychosocial factors associated with 
photoprotection behaviours.
Ethics and dissemination This research has been 
approved by Camden and King’s Cross Research Ethics 
Committee 15/LO/1395. The findings will be published 
in peer-reviewed journals and presented at national and 
international scientific conferences.
IntroductIon
Xeroderma pigmentosum (XP) is a rare auto-
somal recessive inherited condition caused by 
defective nucleotide excision repair. The inci-
dence is 2.3 per million live births in Western 
Europe.1 Patients may develop skin cancers from 
childhood onwards, ocular damage and neuro-
logical deterioration2 and many patients suffer 
abnormal severe and easy sunburn reactions.3 
The phenotype is variable and strongly depen-
dent on the complementation group and on the 
mutations.2 Lifespan varies between countries 
and in USA the median age at death is 32 years, 
the main cause of death being skin cancer.4 The 
clinical management of XP relies on rigorous 
photoprotection which is the only means of 
preventing skin cancer and eye disease. To date, 
no research has been conducted to ascertain 
whether rigorous photoprotection is achieved by 
patients. Adherence to photoprotection is poor 
in non-XP survivors of malignant melanoma5 
and anecdotal evidence from clinicians caring 
for patients with XP suggests that patients with 
XP may vary widely in the degree to which they 
photoprotect.
A recent review of photoprotection in 
immunosuppressed patients highlights the 
gap between knowledge of photoprotection 
recommendations and behaviour.6 That the 
generic provision of knowledge is not enough 
to change behaviour has been identified in 
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Protocol
strengths and limitations of this study
 ► This is the first investigation of photoprotection in 
patients with xeroderma pigmentosum (XP).
 ► We use a novel mixed methods approach to 
investigate predictors of photoprotection behaviours 
in XP.
 ► We have created an innovative method to calculate 
dose of ultraviolet radiation reaching the face.
 ► Recruitment of participants may be a challenge, 
although a feature of research in rare diseases.
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recent reviews of adherence interventions across chronic 
conditions.7 Recent research has therefore focused on 
identifying modifiable psychosocial determinants of 
behaviour. A key focus has been the perceptions a person 
holds about their illness8 and treatment.9 These form a 
personal belief model which influences disease-related 
behaviour, including adherence to treatment.10 It is also 
possible, due to the heterogeneity of XP, that there may 
be disease-related differences between and within patients 
that could affect photoprotection behaviour either 
directly or via the beliefs held about the condition. We 
anticipate that poor ultraviolet radiation (UVR) protec-
tion in patients with XP may be critically dependent on 
such psychological, social and disease-related factors and 
that these may be amenable to intervention.
This research uses a mixture of qualitative and quanti-
tative methods to assess levels of photoprotection in this 
population—exploring individuals’ experiences of XP and 
influences on photoprotection behaviours, differences 
between and within individuals over time and individual 
differences in clinical and psychosocial factors. Though 
the typical ‘large sample’ epidemiological studies are 
not possible in such a rare condition, the combination of 
methods contributes a comprehensive understanding and 
gives a unique viewpoint allowing for a whole person perspec-
tive for the variation in photoprotection. This will enable 
the development of individually tailored interventions to 
improve photoprotection and thus improve outcomes.
To investigate whether poor adherence is associated with 
worse medical outcomes, the research needs to incorporate 
a clinical measure. As the causal link between UVR expo-
sure and cancer incidence is not contentious,11 we will focus 
on UVR dose to the face as the most clinically relevant end 
point, combining personal UVR exposure measured by 
UVR dosimetry with a self-reported record of photoprotec-
tion behaviours throughout the day. The research will have 
a meaningful clinical outcome and provides an opportunity 
to test a novel photodermatological measurement approach.
objectives
1. To explore individuals’ experiences of XP and 
influences on photoprotection behaviours.
2. To objectively measure UVR exposure and by adjusting 
for photoprotection behaviours, calculate the UVR 
dose to the face.
3. To identify the psychological, social, disease-specific 
and sociodemographic factors associated with dose of 
UVR to the face.
4. To identify psychological and social predictors 
of within-individual variation in photoprotection 
behaviours over time.
MeThods and analysis
design
The research uses mixed methods: cross-sectional qualita-
tive interviews and self-report questionnaire, longitudinal 
diary study of photoprotection behaviours and potential 
predictors (n-of-1) for 50 days, estimation of UVR dose to 
the face for 21 days.
Participants
A purposive sample of patients diagnosed with XP will be 
recruited from the caseload of the XP specialist service 
at Guy’s & St Thomas’ NHS Foundation Trust, which 
is composed of the majority of known cases with XP in 
the UK (n=93). The aim is to recruit 45 participants—25 
adults and adolescents who are responsible for their 
own photoprotection behaviour and 20 participants 
consisting of children and younger adolescents, plus 
cognitively impaired individuals where a carer is respon-
sible for photoprotection. Individuals will be eligible to 
participate if they have a confirmed diagnosis of XP and 
are aged between 1 and 85 years. Those with inadequate 
English to take part in an interview and not currently 
living in the UK will be excluded. Given the number of 
with people known to have XP, the sample size is based on 
what is deemed feasible rather than on statistical power 
calculations.
Procedure
A research nurse will contact and recruit eligible patients 
by sending them an invitation letter and participant 
information sheet. The main carer will be contacted for 
patients younger than 16 years of age and adults who 
lack the capacity to consent due to XP-related cognitive 
impairment. Age appropriate information sheets will 
be provided. The patients will be called 2 weeks later to 
see if they are interested in taking part. Those with a 
routine appointment at the XP clinic will be approached 
at the clinic. Patients wishing to participate will complete 
written informed consent.
As shown in figure 1, adult participants will be visited by 
research staff a maximum of three times. The following 
describes the detailed procedure of the adult protocol in 
order of visit. Visits will occur at a convenient time for 
the participant although visit 2 will be between May and 
mid-July (in both 2016 and 2017) to ensure that dosime-
ters are recording when UVR levels are typically at their 
highest in the UK. Visit 3 will occur after all assessments 
have been completed.
Visit 1:
Semistructured interviews will be conducted to gain a 
comprehensive understanding of the meanings of XP 
and the influences on individuals' photoprotection 
behaviours including perceptions of risk, experiences 
of stigma and the role and processes of informal social 
support. Interviews will take place in a private room in 
the patient’s house and participants will be interviewed 
on their own by a researcher, unless they are under 16 
years when they will be interviewed with a parent or 
carer. Carers of adults with cognitive impairment will be 
interviewed if patients are unable to take part due to the 
extent of their impairment. A topic guide will cover the 
participant’s personal story of XP, nature of the burden, 
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Figure 1 Diagram of data collection protocol (2016, 2017). UVR, ultraviolet radiation.
photoprotection behaviours, impact of XP on everyday 
life, perception of UVR risk and social environment. The 
topic guide will provide a flexible framework to structure 
the discussion but the direction of the interview will be 
led by the participant.
Visit 2
The nurse will complete the registration process for 
the daily online (n-of-1) questionnaire and will explain 
how to use the UVR protection diary. Both of these daily 
assessments need to be completed every evening for 50 
days. They will be given the dosimeter and instructed to 
wear it when they go outside for a minimum of 21 days. 
This ‘dosimetry period’ was shorter than the 50-day 
‘daily photoprotection period’ (assessment of predic-
tors and behaviours) due to concerns from the Patient 
and Public Involvement (PPI) panel about participant 
burden. Participants will have the opportunity to wear 
the dosimeter for up to 50 days if they wish. To obtain 
a measurement of routine use of sunscreen the partici-
pant will be supplied with their preferred brand which 
will be weighed before use. Participants will be instructed 
to only use this sunscreen during the dosimetry period. 
Participants will be given a cross-sectional questionnaire 
to complete during the visit or in the period between 
visits 2 and 3.
Visit 3
Materials will be collected and used sunscreen bottles will 
be weighed to calculate the amount used. The anatom-
ical location (ie, face, neck, hands) of the sunscreen used 
will be recorded. Research staff will conduct cognitive 
tests. XP-related data will be collected from clinical files 
held at the XP service. To avoid unnecessary partici-
pant burden, participants younger than 16 years and 
those with cognitive impairment will complete fewer 
assessments across fewer visits, the daily online (n-of-1) 
questionnaire will not be completed and fewer cognitive 
tests will be conducted. Carers will complete the UVR 
protection diary and the cross-sectional questionnaire 
about the participant, if they are either too young or lack 
the capacity to do it themselves.
Materials
(a) The UVR electronic dosimeter (SunSaver 3, Bispeb-
jerg Hospital, Copenhagen, Denmark) is worn on the 
wrist and provides real-time measurements of the UVR 
level in the patient’s environment.12 It has been shown 
to be a reliable measure of personal UVR exposure 
behaviour in healthy individuals13 and melanoma survi-
vors.5 It measures UVR exposure (SEDs), movement 
(number of movements) and temperature (°C) every 5 s 
and records the mean every 5 min.
(b) The daily online (n-of-1) questionnaire is accessed 
through a SMART phone or an internet-linked computer. 
Text messages containing a link to the online question-
naire are delivered daily to the participant’s phone/
device using SurveySignal, at their preferred time; the 
survey is administered using the Qualtrics software (Qual-
trics, Provo, Utah, USA) platform. It uses touch screen 
technology with all questions using a slider scale.
(c) The daily UVR protection diary will be used to 
record time spent outside, specific photoprotection 
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behaviours and the type of outdoor activity. The protec-
tion diary was based on an adapted version of the UK 
Office of National Statistics Time Use Survey,14 with 
the aim of improving the reliability and validity of the 
diary formats used in previous studies which require 
a dichotomous response to a question about each day 
(eg, Did you use sunscreen today ? Y/N), by recording the 
duration of each behaviour. It is a paper diary where 
each page represents 1 day. It has a grid format with the 
day split into 15 min segments starting from 06:00 to 
22:00 hours to ensure all daylight hours are included. 
Participants will record their time spent outside 
(>10 min) rounded to the nearest 15 min (ie, between 
10 and 15 min are recorded as 15 min) and their photo-
protection behaviours for the face (visor, hat, hoodie 
worn-up, glasses, scarf or face buff, sunscreen, lip-block) 
during that time. Participants will draw a line to repre-
sent the amount of time they wore each clothing item 
and tick when they applied sunscreen or lip-sunblock. 
This will allow multiple behaviours to be recorded for 
the same time period. To understand what people were 
doing when they were outside, participants will record 
activities against a prespecified list (eg, socialising with 
friends). A copy of the UVR protection diary is included 
in the online supplementary appendix 1 .
Measures
Predictor variables
Demographic and clinical data
A range of XP-related variables likely to affect photo-
protection behaviours and therefore UVR dose will 
be collected from medical records. This includes XP 
complementation group (genotype, DNA repair activity), 
the presence or absence of XP-related cognitive impair-
ment, severity of eye and neurological disease, severity 
of sunburn,3 cancer number and type of skin and eye 
cancers, age at diagnosis (clinical and when confirmed 
by laboratory testing), years since diagnosis and age when 
photoprotection started. Demographic data (age, gender, 
ethnicity, presence or absence of family member with XP) 
will be collected.
Cognitive ability
To investigate the impact of general cognitive ability 
and higher level thinking processes on photoprotec-
tion behaviours, cognitive testing will be undertaken 
using a standardised test of IQ (Wechsler Abbreviated 
Scale of Intelligence (WASI-II))15 and two tests sensitive 
to executive functioning (Delis-Kaplan Executive Func-
tion System).16 The two subtest version of the WASI-II 
(FSIQ-2, Vocabulary and Matrix Reasoning) will be used 
to give an estimate of general intellectual functioning 
in participants aged 6 years or older and with sufficient 
cognitive capacity to engage in testing. The verbal fluency 
(phonemic and semantic) and the Tower of London tasks 
will test response generativity, planning and monitoring, 
in participants aged 16 years or older.
Psychological and social factors
A variety of psychological and social variables will be 
assessed by a cross-sectional self-report questionnaire. As 
no prior research has investigated predictors of photo-
protection in XP, the variables have been selected on 
the basis of relevant psychological theories and research 
examining photoprotection in healthy populations.17
1. Perceptions of XP: Adapted Brief Illness Perception 
Questionnaire,18 measuring perceptions of XP 
(consequences, timeline, personal and treatment 
control, identity, coherence and emotional response) 
on a 0–10 scale.
2. Treatment beliefs: Adapted version of Beliefs about 
Medicine Questionnaire19 to assess beliefs about the 
necessity of photoprotection and concerns about 
photoprotecting. Respondents state the extent to 
which they agree with statements on a five-item scale.
3. Intention (motivation), self-efficacy (confidence) 
and habit: These factors are assessed for each 
photoprotection behaviour by recording the strength 
of agreement with statements (eg, I intend to wear a 
visor; I am confident I could wear a visor; Every time I 
got ready to go outside, wearing a visor was something 
I did automatically without thinking) on a 7-point 
scale. Intention and self-efficacy items are adapted 
from a manual for the design of questionnaires based 
on the Theory of Planned Behaviour.20 Habit items 
are adapted from the Self-Report Habit Index.21
4. Social support: The level of support and satisfaction 
with it is recorded using two items adapted from 
Social Support Questionnaire22 on a 5-point scale (eg, 
How satisfied are you with the support or help that 
you have to help you with your UV protection? Very 
dissatisfied to very satisfied).
5. Emotional well-being, quality of life and time 
perspective (ie, if decisions are based on present or 
future consequences) will be measured using standard 
scales: Short-form Warwick-Edinburgh Mental Well-
Being Scale (SWEMWBS),23 EQ-5D-5L,24 Adapted 
Zimbardo Time Perception Inventory.25 26
The questionnaire includes disease-related factors, 
financial costs of XP to the participant and a measure of 
adherence to photoprotection behaviours (these data will 
be analysed as part of an international survey of predic-
tors of photoprotection in XP and will be used to validate 
responses on the UVR protection diary) (see online 
supplementary appendix 2).
A range of psychological and social variables are 
measured in the daily online (n-of-1) questionnaire. Ques-
tions will be selected as described in (3), informed by the 
content of initial qualitative interviews and on the like-
lihood of variation over time (eg, stress). The following 
environmental, physical and psychological (cognitive and 
emotional) constructs, as related to UVR protection, will 
be measured: perception of weather, symptoms, rumina-
tion, social support, negative consequences (eg, missing 
out), effort, automaticity, goal conflict, self-consciousness, 
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mental exhaustion, stress, energy, mood and quality of 
life, all reported retrospectively at the end of the day. 
Prospective questions related to photoprotection on the 
next day will assess motivation, confidence, goal priority 
and planning. The stem ‘Thinking about protecting your face 
from UVR when you went outside today/go outside tomorrow…’ 
preceded each question; for example, ‘How much stress 
has it caused you?’ All questions were answered on a 0–100 
sliding scale (see online supplementary appendix 3).
outcome variables
Mean daily UVR dose to the face (standard erythema dose (SED))
The face is the site of the overwhelming majority of skin 
cancers in XP, so the most clinically relevant measure is 
the dose of UVR to facial skin. This will be captured by 
combining data from the UVR dosimeter device worn on 
the wrist, with participants’ UVR protective behaviours 
recorded in the UVR protection diary and the weight 
of sunscreen used during the study period. Combining 
dosimeter and diary is an approach that has been used to 
validate self-report diary data of sun exposure behaviour,27 
to relate personal UVR exposure to different activities 
(eg, work, leisure),28 and to calculate site-specific dose.29 
However, the outcome in those studies was the dose at 
the wrist, whereas this study will combine that data with 
the photoprotection behaviours recorded on the UV 
protection diary, to calculate the proportion of the envi-
ronmental UV dose which reaches the face.
The dosimeter measures the SED every 5 s and gives the 
average of these measurements every 5 min. These are 
combined to provide total UVR exposure for the 15-min 
intervals relating to the periods specified in the activity 
diary. During each 15-min interval, the dose of UVR to 
the face (in SEDs) equals the UVR exposure recorded by 
the dosimeter weighted by the protection associated with 
photoprotection behaviours recorded for that interval on 
the daily UVR protection diary.
Weights will be generated based on the degree of 
photoprotection afforded by each photoprotection prac-
tice, informed by a review of published literature and 
photodermatology expert judgement. To account for 
protective behaviours selectively protecting different 
areas, the weights are produced by separating the face 
into five different regions. This comprised the forehead 
(upper third), nose and cheeks (middle third), chin and 
jaw (lower third), eyes and lips. Each of the three facial 
segments contributes 30% towards the photoprotection 
weighting for the whole face, with lips and eyes contrib-
uting 5% each. Where no protection is used, the weight 
given is 1 and the UVR dose to the face equals the total 
UVR exposure for the interval. Virtually no UVR in the 
range 290–400 nm was measured to penetrate the UVR 
protective visor (unpublished data). Therefore, where 
a visor is indicated to have been worn, since it protects 
all five regions of the face, the weight assigned is 0 and 
the UVR dose to the face is 0 SED. Other combinations 
of behaviours provide selective coverage to different 
regions—for example, glasses were assumed to protect 
only the eyes and a scarf or face buff the lower third of the 
face and lips. Protection provided by a hat is modelled 
based on the position of the sun in the sky relative to the 
person’s home address. Given the latitude of the UK, a 
hat with typical brim effectively provides protection only 
to the forehead.
The level of protection provided by sunscreen to all 
thirds of the face and lip block to the lips is modelled 
separately, with a reducing function over time. Given 
previous research indicates that sunscreen is typically 
applied at 20%–50% of the 2 mg/cm2 thickness required 
to achieve the stated sun protection factor (SPF) ,11 
we will assume patients with XP apply sunscreen at 
approximately 40% thickness (ie, 0.8 mg/cm2). Since 
all individuals will be provided with broad-spectrum 
sunscreen SPF 50+, and there is a square-root association 
between thickness and SPF, we will assume that 20.8% of 
UVR exposure reached the face at the time sunscreen is 
initially applied. The level of protection is conservatively 
assumed to reduce following a linear function with no 
protection provided 8 hours after initial application. The 
assumptions concerning thickness will be examined by 
comparison with the average amount of sunscreen used 
by each participant, as measured by weighing the tubes of 
sunscreen provided at visit 1.
Adherence to photoprotection advice using the daily online (n-of-1) 
questionnaire and UVR protection diary
Adherence to photoprotection advice will be assessed as 
a standalone outcome using both self-report (single item: 
How much have you protected your face from UVR?) on the 
online daily questionnaire and the daily photoprotec-
tion behaviours reported in the UVR protection diary. 
The clinical team will be asked to estimate the adequacy 
of the protection provided by different combinations of 
behaviours (eg, hat and glasses). Participants will also be 
asked to report their satisfaction with their protection on 
the online questionnaire.
Analysis
As shown in table 1, the different data collection methods 
will be used and combined as required to achieve the 
research objectives. Analysis for calculation of UVR dose 
to the face is described in Outcomes I.
To explore individuals’ experience of XP and influences on 
photoprotection behaviours
The qualitative analysis will provide an in-depth explo-
ration of individuals ‘experience of photoprotection 
behaviours in a population with a lack of previous 
research. All interviews will be audio-recorded, 
transcribed and entered into NVivo10. A thematic 
‘framework’ analysis will be undertaken which will 
involve a detailed examination of patterns within and 
across cases. This requires an iterative dynamic process 
of consistently testing and refining themes and expla-
nations and involves ongoing discussions between 
researchers. The validity of emerging explanations and 
 o
n
 21 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-018364 on 21 August 2017. Downloaded from 
6 Walburn J, et al. BMJ Open 2017;7:e018364. doi:10.1136/bmjopen-2017-018364
Open Access 
Table 1 Combination of data collection methods for study objectives
Objectives
To explore 
individuals’ 
experience of XP 
and influences on 
photoprotection 
behaviours.
To objectively measure 
UVR exposure and 
by adjusting for 
photoprotection 
behaviours, calculate 
the UVR dose to the 
face.
To identify the 
psychological and 
social, disease-specific 
and sociodemographic 
factors associated with 
dose of UVR to the face.
To identify 
psychological and 
social predictors 
of within-individual 
variation in 
photoprotection 
behaviours over time.
Qualitative interviews X
Cross-sectional 
questionnaire
X
Daily online (n-of-1) 
questionnaire
X
Daily UVR protection 
diary
X X
Sunscreen weight X
Dosimeter X
Cognitive tests X
Sociodemographic and 
clinical data
X
UVR, ultraviolet radiation; XP, xeroderma pigmentosum.
categories will be examined through triangulation based 
on discussion groups held with clinical staff of the XP 
service.
To identify the psychological, social and disease-specific factors 
associated with dose of UVR to the face in people with XP
When examining the UVR dose to the face, the total UVR 
exposure and estimated UVR dose to the face are summed 
so that the unit of analysis will be the total level per day 
for each individual. Mixed-effects longitudinal models 
will examine the association of clinical and psychosocial 
factors with the average daily UVR dose. Given that daily 
UVR exposure and dose to the face are unlikely to be 
normally distributed, an appropriate generalised model 
will be used (eg, lognormal). Analyses will control for 
total daily environmental UVR (provided by the Public 
Health England Solar Network monitoring station with 
the shortest geodetic distance to the participant’s home 
address (mean 43.3 miles)) and will be stratified by 
whether the photoprotection diary was completed by 
the participant or their carer. Since the level of adher-
ence to photoprotection, in terms of the proportion of 
UVR exposure protected from reaching the face, is the 
ratio of estimated UVR dose to the face to the total UVR 
exposure, the parameter estimates from models for each 
outcome will be combined to provide an indication of the 
effect of the predictor on photoprotection adherence. 
This allows for consideration of whether the effect of the 
predictor is on the total UVR exposure, which is driven 
by time spent outside, or UVR dose to the face, which 
is driven by time spent outside and photoprotection 
behaviours while outside.
To identify psychological and social predictors of within-individual 
variation in photoprotection behaviours over time
The analysis of within-participant variability in photo-
protection behaviours over time (n-of-1 methodology30) 
achieves statistical power by the number of repeated obser-
vations (ie, completion of daily online questionnaire and 
photoprotection diary) throughout time, which in this 
type of analysis represents the sample size.31 The analysis 
will identify factors that may result in fluctuation in an 
individual’s photoprotection adherence and provides a 
fine-grained understanding of the within-person varia-
tion in photoprotection behaviours and the psychological 
and social predictors of these changes. Objective protec-
tion will be dichotomised for each person to reflect their 
‘best’ protection (defined as the highest level of protection 
achieved and used on at least 10 occasions over the study 
period) versus the rest (ie, behaviours that are less than 
best). The correspondence between objective protection 
used in the first 15 min of each outdoor occasion and each 
predictor will be analysed using dynamic logistic regres-
sion,32 controlling for study day, the order of multiple 
outdoor occasions within the same day and past behaviour 
(photoprotection used on each of the previous two outdoor 
occasions). Dynamic regression uses the past to explain the 
future by including in the model variables that represent 
the predictor, as reported that outdoor occasion (lag 0) 
as well as on the previous occasion(s) (eg, previous occa-
sion—lag 1; two occasions prior—lag 2). This allows for the 
identification of potential delayed effects of these predic-
tors on photoprotection. For participants with limited or 
no variability in photoprotection behaviour, visual inspec-
tion of the predictors will instead be used.
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dIscussIon
To the best of our knowledge, this is the first investiga-
tion of photoprotection in patients with XP. The mixed 
methods approach will provide detailed knowledge of the 
nature and predictors of a hitherto poorly understood 
complex set of behaviours, linked to a novel biologi-
cally relevant outcome in XP. It will advance existing 
approaches used to measure adherence to photoprotec-
tion by combining objective assessment of UVR from a 
dosimeter with self-report data of photoprotection from a 
diary to estimate the dose of UVR that reaches the skin on 
the face. Potential predictors from a range of data sources 
are assessed (eg, cognitive tests, self-report psycholog-
ical variables measured cross-sectionally and daily) and 
combined.
The multimethods approach will provide a unique and 
rich understanding of the processes underpinning and 
influencing photoprotection behaviours. These findings 
will be used to inform the development of a behaviour 
change intervention designed to improve photoprotec-
tion. The additional insight provided by mixed methods 
research is recommended by published frameworks 
developed to guide systematic intervention development 
(eg, Intervention Mapping33). A consensus conference, 
attended by researchers, PPI representatives and the XP 
clinical team, will be undertaken to decide which of the 
identified predictors are modifiable and will be targeted 
in a series of individually tailored interventions to improve 
photoprotection in patients with XP.
It is acknowledged that participant recruitment to a 
study involving multiple data collection procedures might 
be challenging. This is particularly pertinent considering 
the rareness of XP whereby half of the UK XP popula-
tion is required to participate. However, the research 
team have worked closely with the PPI Panel and XP clin-
ical team adapting the protocol to ensure that the study 
presents a tolerable and practical ‘patient burden’. It is 
anticipated that the findings of this research will be gener-
alisable to other conditions requiring photoprotection or 
a high degree of adherence to complex behaviours. 
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